f

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore. Excepteur sint lorem cupidatat.

You may like:

Therapeutic Advances in Psoriasis and Psoriatic Arthritis

Therapeutic Advances in Psoriasis and Psoriatic Arthritis

This 30-minute online activity involved an audio-recorded presentation with slides focused on advances in treatment of psoriasis, trends in biologic use in psoriasis, treat to target recommendations, screening patients with psoriasis for psoriatic arthritis, and treatment of psoriatic arthritis by disease domain.

  • April Armstrong, MD, MPH
    Associate Dean for Clinical Research,
    Associate Professor of Dermatology,
    Director of Clinical Research, Clinical and Translational Science Institute
    Director of Clinical Trials and Outcomes Research,
    Director of Psoriasis Program,
    Department of Dermatology
    Keck School of Medicine of USC
    Los Angeles, California

Disclosure and Conflict of Interest Resolution

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the launch of this activity.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

  • Planners (Forefront Collaborative): Miranda Armie and Marianna Shershneva, MD, PhD

The following individuals have disclosed that they and/or their spouse/partner have had a financial relationship in the past
12 months:

  • Planner (Forefront Collaborative): Lilia Zurkovsky, PhD, has personal stock in Teva Pharmaceutical Industries
  • Faculty: April Armstrong; Consultant for Pfizer, Celgene, Merck

As a result of participation in this educational activity, participants should increase their ability to:

  • identify

    Identify advances in biologic therapies for moderate-to-severe plaque psoriasis

  • Determine the importance of treating-to-target and comparative effectiveness in psoriasis management

  • Screen psoriasis patients for psoriatic arthritis

Resources

There are no resources listed for this course at this time.

Activity Information

Target Audience
The target audience for this educational activity was nurse practitioners and physician assistants who specialize in dermatology. Dermatologists and other clinicians who are members of the healthcare team providing care for patients with psoriasis may have benefited from participation in this education.

Accreditation Statement
Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Forefront Collaborative designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Interstate Postgraduate Medical Association is approved by the California Board of Registered Nursing, Provider Number 6971, for 0.6 contact hours. Each person should retain this certificate for 4 years after the course has been completed. RNs outside of California must verify with their licensing agency for approval of this course.

This activity is approved 0.5 contact hours of continuing education, which includes 0.42 hours of pharmacology, by the American Association of Nurse Practitioners. Activity ID 17042646. This activity was planned in accordance with AANP CE Standards and Policies.

CME Content Review
The content of this activity was independently peer reviewed. The reviewers of this activity have no relevant financial relationships to disclose.

This continuing medical education activity may have included reference(s) to unlabeled or unapproved uses of drugs.

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative, Interstate Postgraduate Medical Association, and Lilly.

Provider
This activity is provided by Forefront Collaborative in collaboration with Interstate Postgraduate Medical Association.

Commercial Support
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.